In vitro pharmacodynamic models to determine the effect of antibacterial drugs

被引:74
作者
Gloede, Julia [1 ]
Scheerans, Christian [1 ,2 ]
Derendorf, Hartmut [3 ]
Kloft, Charlotte [1 ,2 ]
机构
[1] Univ Halle Wittenberg, Inst Pharm, Dept Clin Pharm, D-06120 Halle, Germany
[2] Free Univ Berlin, Inst Pharm, Dept Clin Pharm, D-1000 Berlin, Germany
[3] Univ Florida, Coll Pharm, Dept Pharmaceut, Gainesville, FL 32610 USA
关键词
in vitro models; antibiotics; dilution models; dialysis; diffusion models; static models; RESISTANT STAPHYLOCOCCUS-AUREUS; CULTURE BILAYER MODEL; INVITRO KINETIC-MODEL; PSEUDOMONAS-AERUGINOSA; STREPTOCOCCUS-PNEUMONIAE; ESCHERICHIA-COLI; BACTERICIDAL ACTIVITY; ANTIMICROBIAL AGENTS; AMPHOTERICIN-B; KILL KINETICS;
D O I
10.1093/jac/dkp434
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
In vitro pharmacodynamic (PD) models are used to obtain useful quantitative information on the effect of either single drugs or drug combinations against bacteria. This review provides an overview of in vitro PD models and their experimental implementation. Models are categorized on the basis of whether the drug concentration remains constant or changes and whether there is a loss of bacteria from the system. Further subdifferentiation is based on whether bacterial loss involves dilution of the medium or is associated with dialysis or diffusion. For comprehension of the underlying principles, experimental settings are simplified and schematically illustrated, including the simulations of various in vivo routes of administration. The different model types are categorized and their (dis)advantages discussed. The application of in vitro models to special organs, infections and pathogens is comprehensively presented. Finally, the relevance and perspectives of in vitro investigations in drug discovery and clinical research are elucidated and discussed.
引用
收藏
页码:186 / 201
页数:16
相关论文
共 164 条
[41]  
EDEN T, 1985, SCAND J INFECT DIS, P46
[42]  
Ellen R P, 1997, Adv Dent Res, V11, P33
[43]  
*EMEA, 2000, CPMPEWP265599 EMEA
[44]   EVALUATION OF 2 METHODS FOR OVERCOMING THE ANTIBIOTIC CARRY-OVER EFFECT [J].
ENG, RHK ;
SMITH, SM ;
CHERUBIN, CE ;
TAN, EN .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1991, 10 (01) :34-38
[45]   Quantification of Staphylococcus aureus and Escherichia coli in the liquid medium by fluorimetry and its use in phagocytosis assay [J].
Fang, W .
JOURNAL OF APPLIED BACTERIOLOGY, 1996, 80 (06) :577-582
[46]   INVIVO ANTIBIOTIC SYNERGISM - CONTRIBUTION OF ANIMAL-MODELS [J].
FANTIN, B ;
CARBON, C .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (05) :907-912
[47]   IN-VITRO AND EX-VIVO ACTIVITIES OF ANTIMICROBIAL AGENTS USED IN COMBINATION WITH CLARITHROMYCIN, WITH OR WITHOUT AMIKACIN, AGAINST MYCOBACTERIUM-AVIUM [J].
FATTORINI, L ;
LI, B ;
PIERSIMONI, C ;
TORTOLI, E ;
XIAO, Y ;
SANTORO, C ;
RICCI, ML ;
OREFICI, G .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (03) :680-685
[48]  
FDA, 1998, GUID IND DEV ANT DRU
[49]   Establishment of a real-time PCR-based approach for accurate quantification of bacterial RNA targets in water, using Salmonella as a model organism [J].
Fey, A ;
Eichler, S ;
Flavier, S ;
Christen, R ;
Höfle, MG ;
Guzmán, CA .
APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 2004, 70 (06) :3618-3623
[50]  
Firsov A., 2007, Antimicrobial Pharmacodynamics in Theory and Clinical Practice, VSecond, P45